Li DD - Search Results

1

Targeting protein-protein interaction between MLL1 and reciprocal proteins for leukemia therapy.

Wang ZH, Li DD, Chen WL, You QD, Guo XK. Wang ZH, et al. Among authors: li dd. Bioorg Med Chem. 2018 Jan 15;26(2):356-365. doi: 10.1016/j.bmc.2017.11.045. Epub 2017 Dec 1. Bioorg Med Chem. 2018. PMID: 29254892 Review.

2

Novel 5-carboxy-8-HQ based histone demethylase JMJD2A inhibitors: introduction of an additional carboxyl group at the C-2 position of quinoline.

Feng T, Li D, Wang H, Zhuang J, Liu F, Bao Q, Lei Y, Chen W, Zhang X, Xu X, Sun H, You Q, Guo X. Feng T, et al. Eur J Med Chem. 2015 Nov 13;105:145-55. doi: 10.1016/j.ejmech.2015.09.013. Epub 2015 Sep 10. Eur J Med Chem. 2015. PMID: 26491978

3

Discovery of DDO-2213 as a Potent and Orally Bioavailable Inhibitor of the WDR5-Mixed Lineage Leukemia 1 Protein-Protein Interaction for the Treatment of MLL Fusion Leukemia.

Chen W, Chen X, Li D, Zhou J, Jiang Z, You Q, Guo X. Chen W, et al. J Med Chem. 2021 Jun 24;64(12):8221-8245. doi: 10.1021/acs.jmedchem.1c00091. Epub 2021 Jun 9. J Med Chem. 2021. PMID: 34105966

4

Discovery of a potent MLL1 and WDR5 protein-protein interaction inhibitor with in vivo antitumor activity.

Chen W, Chen X, Li D, Wang X, Long G, Jiang Z, You Q, Guo X. Chen W, et al. Eur J Med Chem. 2021 Nov 5;223:113677. doi: 10.1016/j.ejmech.2021.113677. Epub 2021 Jun 28. Eur J Med Chem. 2021. PMID: 34225179

5

Design, synthesis, and initial evaluation of affinity-based small molecular probe for detection of WDR5.

Chen WL, Li DD, Wang ZH, Xu XL, Zhang XJ, Jiang ZY, Guo XK, You QD. Chen WL, et al. Among authors: li dd. Bioorg Chem. 2018 Feb;76:380-385. doi: 10.1016/j.bioorg.2017.11.018. Epub 2017 Nov 28. Bioorg Chem. 2018. PMID: 29241110

6

Proton pump inhibitors selectively suppress MLL rearranged leukemia cells via disrupting MLL1-WDR5 protein-protein interaction.

Chen WL, Li DD, Chen X, Wang YZ, Xu JJ, Jiang ZY, You QD, Guo XK. Chen WL, et al. Among authors: li dd. Eur J Med Chem. 2020 Feb 15;188:112027. doi: 10.1016/j.ejmech.2019.112027. Epub 2019 Dec 31. Eur J Med Chem. 2020. PMID: 31923859

7

Structure-based design and synthesis of small molecular inhibitors disturbing the interaction of MLL1-WDR5.

Li DD, Chen WL, Xu XL, Jiang F, Wang L, Xie YY, Zhang XJ, Guo XK, You QD, Sun HP. Li DD, et al. Eur J Med Chem. 2016 Aug 8;118:1-8. doi: 10.1016/j.ejmech.2016.04.032. Epub 2016 Apr 13. Eur J Med Chem. 2016. PMID: 27116709

8

G9a - An Appealing Antineoplastic Target.

Chen WL, Sun HP, Li DD, Wang ZH, You QD, Guo XK. Chen WL, et al. Among authors: li dd. Curr Cancer Drug Targets. 2017;17(6):555-568. doi: 10.2174/1568009616666160512145303. Curr Cancer Drug Targets. 2017. PMID: 27174055 Review.

9

High-affinity small molecular blockers of mixed lineage leukemia 1 (MLL1)-WDR5 interaction inhibit MLL1 complex H3K4 methyltransferase activity.

Li DD, Chen WL, Wang ZH, Xie YY, Xu XL, Jiang ZY, Zhang XJ, You QD, Guo XK. Li DD, et al. Eur J Med Chem. 2016 Nov 29;124:480-489. doi: 10.1016/j.ejmech.2016.08.036. Epub 2016 Aug 20. Eur J Med Chem. 2016. PMID: 27598236

10

Structure-based design of ester compounds to inhibit MLL complex catalytic activity by targeting mixed lineage leukemia 1 (MLL1)-WDR5 interaction.

Li DD, Wang ZH, Chen WL, Xie YY, You QD, Guo XK. Li DD, et al. Bioorg Med Chem. 2016 Nov 15;24(22):6109-6118. doi: 10.1016/j.bmc.2016.09.073. Epub 2016 Oct 1. Bioorg Med Chem. 2016. PMID: 27720555

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

893 results

Search Page